Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
N Lecrenier, P Beukelaers, R Colindres… - Expert review of …, 2018 - Taylor & Francis
Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine
(Shingrix, RZV) to protect people aged≥ 50 years (50+) against herpes zoster (HZ) and its …
(Shingrix, RZV) to protect people aged≥ 50 years (50+) against herpes zoster (HZ) and its …
Zoster vaccine: current status and future prospects
MN Oxman - Clinical infectious diseases, 2010 - academic.oup.com
Abstract Live, attenuated Oka/Merck varicella-zoster virus (VZV) vaccine (zoster vaccine)
protects immunocompetent adults from herpes zoster and its complications. Success of …
protects immunocompetent adults from herpes zoster and its complications. Success of …
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
H Lal, AL Cunningham, O Godeaux… - … England Journal of …, 2015 - Mass Medical Soc
Background In previous phase 1–2 clinical trials involving older adults, a subunit vaccine
containing varicella–zoster virus glycoprotein E and the AS01B adjuvant system (called …
containing varicella–zoster virus glycoprotein E and the AS01B adjuvant system (called …
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study
EM Berkowitz, G Moyle, HJ Stellbrink… - The Journal of …, 2015 - academic.oup.com
Background. Human immunodeficiency virus (HIV)–infected individuals are at increased risk
of herpes zoster (HZ), even in the antiretroviral therapy (ART) era. Because concerns exist …
of herpes zoster (HZ), even in the antiretroviral therapy (ART) era. Because concerns exist …
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
EA Stadtmauer, KM Sullivan, FM Marty… - Blood, The Journal …, 2014 - ashpublications.org
Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ
vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer …
vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer …
[HTML][HTML] Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
R Chlibek, K Pauksens, L Rombo, G van Rijckevorsel… - Vaccine, 2016 - Elsevier
Background An investigational subunit vaccine containing the varicella-zoster virus (VZV)
glycoprotein E (gE) and the AS01 B adjuvant system is being evaluated for the prevention of …
glycoprotein E (gE) and the AS01 B adjuvant system is being evaluated for the prevention of …
Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice
N Dendouga, M Fochesato, L Lockman, S Mossman… - Vaccine, 2012 - Elsevier
Lack of adequate cell-mediated immunity (CMI) to varicella-zoster virus (VZV) has been
associated with higher risks of developing herpes zoster (HZ) and associated post-herpetic …
associated with higher risks of developing herpes zoster (HZ) and associated post-herpetic …
Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults≥ 50 years of age
R Chlibek, JM Bayas, H Collins… - The Journal of …, 2013 - academic.oup.com
Background. An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vaccine
candidate for herpes zoster is in development. In this trial we compared the safety …
candidate for herpes zoster is in development. In this trial we compared the safety …
Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe
RG Nowak, PE Gravitt, CS Morrison… - Journal of Infectious …, 2011 - academic.oup.com
Background. Individuals who acquire human immunodeficiency virus (HIV) may experience
an immediate disruption of genital tract immunity, altering the ability to mount a local and …
an immediate disruption of genital tract immunity, altering the ability to mount a local and …
Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells
Purpose: The multiple mechanisms used by solid tumors to suppress tumor-specific immune
responses are a major barrier to the success of adoptively transferred tumor-specific T cells …
responses are a major barrier to the success of adoptively transferred tumor-specific T cells …